SLC5A2 and pancreatic neoplasm: SGLT2 is also expressed in prostate and pancreatic adenocarcinoma, and SGLT2 inhibitors have been shown to suppress glucose absorption and inhibit tumor cell proliferation in a pancreatic cancer model [19].